Clinical trials: Hormone-Refractory Prostate Cancer, open to volunteers
Renal Cell Cancer, Castrate Resistant Prostate Cancer
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care.
- Conditions
- Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
- Trial name
- NCT04969315
- Testing
- TT-10, TT-4
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Portage Biotech
Oligoprogressive Prostate Cancer, Metastatic Prostate Cancer
PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer
PSMA-OLIGO-PRO is a multicenter, ambispective, observational real-world evidence registry of adults with metastatic hormone-sensitive or metastatic castration-resistant prostate cancer who develop a limited number of progressing…
- Trial name
- PSMA-OLIGO-PRO (NCT07691697)
- Testing
- Comprehensive Progression-Directed Radiotherapy
- Where
- Poland
- Volunteers
- 1,000 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA…
- Conditions
- Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases
- Trial name
- NCT06706921
- Testing
- 18F-Fluciclovine PET/CT Scan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Metastatic Castration-resistant Prostate Cancer, mCRPC
3D1015 Injection for Patients With mCRPC
This open-label clinical study investigates 3D1015 Injection (Lu 177-PSMA-3D1015) in adult males with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT07537010
- Testing
- Lu 177-PSMA-3D1015 Injection
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Chunjing Yu
Metastatic Castration-resistant Prostate Cancer
Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy
This study compares two different imaging procedures to each other, one using positron emission tomography (PET) with fluorothymidine F-18 (FLT) (FLT PET for short), and the other using chemical shift-encoded (CSE) magnetic…
- Trial name
- NCT07609225
- Testing
- 3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer Castration-resistant Prostate Cancer
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study introduces a new treatment approach for metastatic castration-resistant prostate cancer, a stage of disease that remains difficult to manage with current therapies.
- Trial name
- NCT07298239
- Testing
- anti-PSMA CAR-NK
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to…
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Carcinoma
- Trial name
- NCT06099093
- Testing
- 18F-DCFPyl
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
NSCLC, Non-Small Cell Lung Cancer
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
Background: Immunotherapy is a type of treatment that works by making the body s own immune system stronger. These treatments are used for cancers such as non small cell lung cancer (NSCLC); thymic carcinoma (TC); or metastatic…
- Conditions
- NSCLC, Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT07902921
- Testing
- STAR0602, Nivolumab
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy…
- Trial name
- NCT04946370
- Testing
- 225Ac-J591, Pembrolizumab, Androgen receptor inhibitor
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Weill Medical College of Cornell University
Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
Bipolar Androgen Therapy + Carboplatin in mCRPC
The purpose of this study is to determine the efficacy of BAT and carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).
- Trial name
- HiTeCH (NCT03522064)
- Testing
- Testosterone Enanthate 100 MG/ML Injectable Solution, Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- St Vincent's Hospital, Sydney
Metastatic Castration-resistant Prostate Cancer
Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
Taxane efficacy in metastatic prostate cancer is modest due to resistance development. Several clinical phase III studies in metastatic castration-naïve prostate cancer (mCNPC) patients have shown that adding an androgen receptor…
- Trial name
- DAROTAXEL (NCT05762536)
- Testing
- Darolutamide, Docetaxel or cabazitaxel
- Where
- Netherlands
- Volunteers
- 245 people
- Sponsor
- Erasmus Medical Center
Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination…
- Conditions
- Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Trial name
- KAT6 (NCT04606446)
- Testing
- PF-07248144, Fulvestrant, Letrozole
- Where
- 43 sites in United States, Australia and 3 more
- Volunteers
- 320 people
- Sponsor
- Pfizer
Metastatic Castration-resistant Prostate Cancer
Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer
Prostate cancer is the third leading cause of cancer-related death in men in the United States and Europe. The treatment of metastatic castration-resistant prostate cancer (mCRPC) has evolved with the arrival of the radioligand…
- Trial name
- ReaLuP (NCT06866938)
- Testing
- [177Lu]Lu-PSMA-617 (Pluvicto, Novartis)
- Where
- 16 sites in France
- Volunteers
- 58 people
- Sponsor
- Hospices Civils de Lyon
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
The usual approach for most patients who are not in a study is treatment with docetaxel. This study is being done to answer the following question: Can the chance of prostate cancer growing or spreading be lowered by adding a…
- Trial name
- OPTION-DDR (NCT06439225)
- Testing
- Docetaxel, Carboplatin
- Where
- 14 sites in Canada
- Volunteers
- 236 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after…
- Trial name
- PSMAcTION (NCT06780670)
- Testing
- Investigators choice of SoC, AAA817
- Where
- 93 sites in United States, Australia and 11 more
- Volunteers
- 443 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
This is a phase I dose-escalation study of 225Ac-J591 administered together with 177Lu-PSMA small molecule. Both drugs are designed to deliver radiation to prostate cancer cells; they are known as radionuclide conjugates…
- Trial name
- NCT04886986
- Testing
- 225Ac-J591, 177Lu-PSMA-617, 68Ga-PSMA-11
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Weill Medical College of Cornell University
Metastatic Castration-resistant Prostate Cancer
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
This is a pilot study to assess the safety and measure image-based absorbed dose of 177Lu-P17-087/177Lu-P17-088 in patients with metastatic castration-resistant prostate cancer (mCRPC) who will undergo radioliagnd therapy using…
- Trial name
- NCT05603559
- Testing
- 1.1 GBq (30 mCi) of 177Lu-P17-087, 1.1 GBq (30 mCi) of 177Lu-P17-088
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase I trial compares the effect of lutetium Lu 177 (177^Lu)-prostate-specific membrane antigen (PSMA)-617 in combination with Sipuleucel-T to 177^Lu-PSMA-617 alone in treating patients with prostate that has spread from…
- Trial name
- NCT07219147
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B)…
- Conditions
- Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer
- Trial name
- NCT06784193
- Testing
- OP-3136, Fulvestrant, Palazestrant
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 180 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Prostate Cancer
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy.
- Trial name
- NCT04221542
- Testing
- AMG 509, Abiraterone, Enzalutamide
- Where
- 57 sites in United States, Australia and 8 more
- Volunteers
- 479 people
- Sponsor
- Amgen